Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TEAD4 | Q15561 | 2/20 | 0.57 |
| ▸ | TEAD2 | Q15562 | 2/20 | 0.57 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.57 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.57 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.53 |
| ▸ | IDH2 | P48735 | 2/20 | 0.51 |
| ▸ | YAP1 | P46937 | 1/20 | 0.51 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.47 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16481323 | 0.88 | TAS2R14 (0.54) | ALDH1A1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL20552709 | 0.85 | ALDH1A1 (0.61) | ALDH1A1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL28361136 | 0.85 | KCNK18 (0.49) | ALDH1A1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL6211034 | 0.85 | MAPT (0.61) | ALDH1A1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL1921484 | 0.84 | MAPT (0.77) | ALDH1A1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL22718324 | 0.83 | MPO (0.60) | ALDH1A1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL29603147 | 0.83 | MPO (0.60) | ALDH1A1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL20553187 | 0.83 | TEAD1 (0.53) | ALDH1A1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL28978574 | 0.80 | TAS2R14 (0.65) | ALDH1A1GAAMAPTRAB9ASMN1; SMN2 | |
| SCHEMBL20552441 | 0.80 | LMNA (0.47) | ALDH1A1GAAMAPTSMN1; SMN2RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642772-A1 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2025-11-05 | — | — | EP | disclosed |
| WO-2025227032-A1 | METHODS FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES | REMIX THERAPEUTICS INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4431504-A1 | AROMATIC HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Shanghai Institute of Material Medica, Chinese Academy of Sciences (CN) | 2024-09-18 | — | — | EP | disclosed |
| EP-4396176-A1 | INDOLE COMPOUNDS AND USES THEREOF IN THE TREATEMENT OF CYSTIC FIBROSIS | GENZYME CORPORATION (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024141535-A1 | NLRP3 INFLAMMASOME INHIBITORS | ASTRAZENECA AB (SE) | 2024-07-04 | — | — | WO | disclosed |
| EP-4149931-A1 | NUCLIDE LABELLED H-TETRAZINES AND USE THEREOF FOR PET AND SPECT PRETARGETED IMAGING AND RADIONUCLIDE THERAPY | Rigshospitalet (DK) | 2023-03-22 | — | — | EP | disclosed |
| WO-2023034946-A1 | INDOLE COMPOUNDS AND USES THEREOF IN THE TREATEMENT OF CYSTIC FIBROSIS | GENZYME CORPORATION (US) | 2023-03-09 | — | — | WO | disclosed |
| EP-3400228-B1 | FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | TABOMEDEX BIOSCIENCES INC (US) | 2022-04-13 | — | — | EP | disclosed |
| US-11279722-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2022-03-22 | — | — | US | disclosed |
| US-11186554-B2 | Non-fused tricyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-11-30 | — | — | US | disclosed |
| CN-111132673-A | Non-fused tricyclic compounds | 维瓦斯治疗公司 | 2020-05-08 | — | — | CN | disclosed |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279722-B2 | Organic electroluminescent materials and devices | GLRA3, GLRA2, LIFR | ALDH1A1 4105/4885GAA 2095/4885MAPT 4663/4885 |
| US-20200062721-A1 | NON-FUSED TRICYCLIC COMPOUNDS | YAP1, MYC, TEAD2 | ALDH1A1 3497/4885GAA 3437/4885MAPT 1705/4885 |
| US-11186554-B2 | Non-fused tricyclic compounds | YAP1, MYC, TEAD2 | ALDH1A1 3497/4885GAA 3437/4885MAPT 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.